The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Ropeginterferon-alfa2b: Real-world data for the treatment of PV
|
A sub-analysis of the PV-ARC (NCT06134102) retrospective study evaluating real-world data from a small cohort of patients with polycythemia vera (PV) receiving ropeginterferon-alfa2b (ropegIFNα2b) has been published in Annals of Hematology by Palandri et al.1 Among 149 patients with an approved indication for ropegIFNα2b treatment, only 55 (36.9%) met the local Italian reimbursement criteria and 18 (12.1%) received ropegIFNα2b. Data from these 18 patients were analyzed based on risk status. |
| Key learnings |
| After a mean duration of 8.9 months, 66.7% of patients had a complete hematologic response (CHR) to ropegIFNα2b (CHR was higher in patients with low-risk [75%] vs high-risk [50%] PV). |
| The majority of patients (11) required dose increases, with a mean maximum dose of 131.3 µg every 2 weeks for low-risk and 120.8 µg every 2 weeks for high-risk patients. |
| RopegIFNα2b was administered in combination with hydroxyurea (HU) in 39% of patients, with the most common reason for the addition of HU being extreme thrombocytosis. |
| Larger cohorts of data in the real-world setting are required to understand optimal patient selection and management of ropegIFNα2b treatment. However, initial data highlight use of low ropegIFNα2b dose, with frequent need for hydroxyurea combinations; optimizing ropegIFNα2b dose could maximize the therapeutic benefit for patients. |
| The data support the ELN recommendation for use of ropegIFNα2b as a first-line treatment for low-risk PV. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content